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OBJECTIVE: The expression of transcription factors involved in early pituitary development, such as PROP1 and
POU1F1, has been detected in pituitary adenoma tissues. In this study, we sought to characterize the
transcriptional profiles of PROP1, POU1F1, and TBX19 in functioning and nonfunctioning pituitary adenomas in
an attempt to identify their roles in tumorigenesis and hormone hypersecretion.
METHODS: RT-qPCR analyses were performed to assess the transcriptional pattern of PROP1, POU1F1, TBX19,
and hormone-producing genes in tissue samples of corticotrophinomas (n = 10), somatotrophinomas (n = 8),
and nonfunctioning adenomas (n = 6).
RESULTS: Compared with normal pituitary tissue, POU1F1 was overexpressed in somatotrophinomas by 3-fold.
PROP1 expression was 18-fold higher in corticotrophinomas, 10-fold higher in somatotrophinomas, and 3-fold
higher in nonfunctioning adenomas. TBX19 expression was 27-fold higher in corticotrophinomas. Additionally,
the level of TBX19 mRNA positively correlated with that of pro-opiomelanocortin (r = 0.49, p= 0.014).
CONCLUSIONS: Our data demonstrate that PROP1 is overexpressed in pituitary adenomas, mainly in
corticotrophinomas. Together with previously published data showing that patients who harbor PROP1 loss-
of-function mutations present a progressive decline in corticotrope function, our results support a role for
PROP1 in pituitary tumor development and in the maintenance of cell lineages committed to corticotrophic
differentiation.
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& INTRODUCTION
The expression of transcription factors involved in early
pituitary development, such as PROP1 and POU1F1, has
been detected in pituitary adenoma tissues (1-5). Mutations
in these genes have been implicated in the etiology of
combined pituitary hormone deficiency and are associated
with pituitary hypoplasia or hyperplasia (6,7), based on
Magnetic Resonance Imaging (MRI) findings. In adult mice,
the constitutive expression of Prop1 results in delayed
gonadotrophin production and pituitary tumor development
(8). It has been shown that the mutated POU1F1 protein
decreases GH and PRL hypersecretion in the rat pituitary
tumor cell line GH4C1 in vitro. Additionally, reduced GH
secretion and tumor growth is observed in xenografts
obtained after the transplantation of GH4C1 cells expressing
mutant POU1F1 (9).
In this study, we sought to characterize the transcriptional
profiles of PROP1, POU1F1, and TBX19 in functioning and
nonfunctioning pituitary adenomas in an attempt to identify
their roles in tumorigenesis and hormone hypersecretion.
& MATERIALS AND METHODS
Patients and tumor characterization – The cohort was
composed of 24 patients (17 female, 7 male) with positive
clinical, laboratory, and imaging tests for the diagnosis of
pituitary tumors (Table 1). Ten patients had Cushing’s
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disease (7 female, 3 male); 4 cases were due to microadeno-
mas, 5 cases were due to macroadenomas, and 1 patient
developed Nelson’s syndrome. These patients were aged
between 15 and 35 years at the time of surgery. Eight patients
(4 female, 4 male) were diagnosed with acromegaly caused
by macroadenomas and underwent surgery when they were
between 33 and 71 years of age. Six patients were diagnosed
with non-functional macroadenomas (3 female, 3 male) and
were between 47 and 66 years of age at the time of surgery.
RT-qPCR – Following surgical resection of the tumors, total
RNA was extracted using TRIzol (Life Technologies, Carlsbad,
CA, USA) according to the manufacturer’s protocol. Total RNA
pooled from 88 human pituitary glands (Clontech, Mountain
View, CA, USA) was used as a control. We used 5 mg of total
tumor RNA or total human pituitary gland RNA (Clontech) for
cDNA synthesis using the RT2 First Strand Kit (SABiosciences/
Qiagen, Frederick, MD, USA), including the genomic DNA
decontamination step. Real-time PCR reactions were performed
using the RT2 ProfilerTM PCR Array (CAPH09297A;
SABiosciences/Qiagen) and SYBR Green I as the DNA-binding
dye to analyze the transcriptional profile of POU1F1
(NM_001122757) and PROP1 (NM_006261) and hormone
producing genes (GH - NM_000515, POMC - NM_001035256,
PRL - NM_000948, TSHB - 000549, FSHB - NM_000510, LH -
NM_000894 and CGA - NM_000735). The first-strand cDNA
was subjected to PCR under the following conditions: 95 C˚ for
10 min and 40 amplification cycles of 95 C˚ for 15 s and 60 C˚ for
1 min, followed by a melting curve analysis. The expression
levels of POUF1 and PROP1 relative to those in the normal
pituitary gland were calculated by the 2-DDCT method using the
Ct geometric means of eight endogenous genes (ACTB,
NM_001101; B2M, NM_004048; GAPDH, NM_002046;
HPRT1, NM_000194; PGK1, NM_000291; PPIA, NM_021130;
RPL13A, NM_012423; and TBP, NM_003194).
The transcriptional level of TBX19 (also known as TPIT) was
also analyzed in the tumor samples using a TaqManH Gene
Expression Assay (TBX19 FAM, Hs01113611_m1; Applied
Biosystems, Carlsbad, CA, USA). We used 2 mg of total tumor
RNA or total human pituitary gland RNA (Clontech) for cDNA
synthesis using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). The PCR protocol consisted of 50 C˚
for 2 min, denaturation at 95 C˚ for 10 min, followed by 40
amplification cycles of 95 C˚ for 15 s and 60 C˚ for 60 s. The
expression of TBX19 in the tumor samples relative to that in the
normal pituitary gland was calculated using the 2-DDCT method
using the Ct geometric means of three endogenous genes (PPIA,
Hs99999904_m1; PGK1, Hs99999906_m1; and HPRT1,
Hs99999909_m1). The TaqManH Gene Expression Assay con-
sisted of hybridization probes that span the exon/exon
boundaries. Genomic DNA was used as a negative control.
Genes with a fold change of $2.5 were considered to be
differentially expressed. The PCR reactions were performed
with an ABI PRISM 7000 Sequence Detection System
(Applied Biosystems, Carlsbad, CA, USA). Quantitative
measurements were performed in quadruplicate.
Statistical analysis – The relative expression values of PROP1,
POU1F1, and TBX19 were analyzed by one-way ANOVA.
Bonferroni correction was applied to assess the significant
difference between the tumoral groups, and the differences
were considered statistically significant at a p-value of ,2.5%
(p,0.025). Pearson’s correlation coefficient was applied to
assess the relationship of PROP1, POU1F1, and TBX19 with
the expression of the hormone-producing genes GH, ACTH,
PRL, TSH, FSH, LH, and aGSU. The statistical analyses were
performed using BioEstat 5.0 software (National Institute of
Space Research – INPE, Sa˜o Jose´ dos Campos/SP, Brazil).
& ETHICS
All participants provided written informed consent, and
the protocol was approved by the Human Research Ethics
Committee of the Medical School of the University of Sa˜o
Table 1 - Clinical and pathological features of the tumor samples.
Patient Clinical features Sex Age (years) Tumor size (cm) Immunohistochemistry1
1 Nelson’s Syndrome F 33 .1.0 ACTH 3+
2 Cushing’s Disease F 35 1.8 ACTH 3+
3 Cushing’s Disease M 16 0.9 ACTH 2+
4 Cushing’s Disease M 18 1.0 ACTH 3+
5 Cushing’s Disease F 27 2.0 ACTH 3+
6 Cushing’s Disease F 24 1.0 ACTH 3+
7 Cushing’s Disease F 34 0.6 ACTH 2+
8 Cushing’s Disease F 34 1.0 ACTH 2+
9 Cushing’s Disease M 15 0.4 ACTH 2+
10 Cushing’s Disease F 19 0.6 ACTH 2+
11 Acromegaly M 71 1.7 GH 3+, FSH 1+
12 Acromegaly M 45 6.4 GH 3+, PRL 3+
13 Acromegaly M 33 1.2 GH 3+, LH 2+, FSH 2+
14 Acromegaly M 40 5.9 GH 2+, PRL 1+
15 Acromegaly F 37 2.2 GH 3+, LH 1+, TSH 1+, PRL 3+
16 Acromegaly F 59 1.1 GH 3+
17 Acromegaly F 53 2.2 GH 3+, FSH 1+, TSH 1+
18 Acromegaly F 54 7.0 GH 3+, FSH 1+
19 Nonfunctioning adenoma M 51 2.5 TSH 1+
20 Nonfunctioning adenoma F 50 2.6 TSH 2+
21 Nonfunctioning adenoma M 56 3.4 LH 1+, FSH 1+
22 Nonfunctioning adenoma F 66 3.3 -
23 Nonfunctioning adenoma F 47 2.4 -
24 Nonfunctioning adenoma M 62 6.0 GH 1+, ACTH 1+
1Immunostaining was performed using anti-pituitary hormone antibodies. Immunostaining was evaluated on each slide using a semiquantitative scale as
follows: -, no immunostaining; 1+, 1 to 10% immunoreactive cells; 2+, 11 to 50% immunoreactive cells; 3+, .50% immunoreactive cells.
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Paulo. The clinical investigations were conducted according
to the principles in the Declaration of Helsinki.
& RESULTS
Analysis of the RT-qPCR array showed that PROP1 was
overexpressed in the tumor samples compared to the
control. The expression of PROP1 was approximately 18-
fold higher in the corticotrophinomas, 10-fold higher in the
somatotrophinomas, and 3-fold higher in the nonfunction-
ing adenomas (ANOVA: F = 6.8, p= 0.005). On the other
hand, POUIF1 was overexpressed only in the somatotro-
phinomas (3-fold higher; ANOVA: F = 5.0, p= 0.016)
(Figure 1). Pro-opiomelanocortin (POMC), the peptide
precursor of adrenocorticotropin (ACTH), was overex-
pressed in the corticotrophinomas (65-fold higher), while
GH was constitutively expressed in almost all of the
somatotrophinoma samples. The expression of hormone-
producing genes was downregulated in the nonfunctioning
adenomas (Figure 2). Because PROP1 was upregulated in
the corticotrophinomas, the mRNA level of TBX19 (which is
only expressed in cells committed to corticotrope and
melanotrope differentiation) was analyzed using a
TaqManH Gene Expression Assay in the same samples
analyzed with the RT-qPCR array (Figure 3). As expected,
the expression of TBX19 in the corticotrophinomas was, on
average, 27-fold higher than in the control (ANOVA: F = 9.6,
p= 0.001). The somatotrophinomas exhibited constitutive
Figure 1 - Transcriptional profile of PROP1 and POU1F1 in
pituitary adenomas. Analysis of the RT-qPCR array showed that
PROP1 expression was 18-fold higher in the corticotrophinomas,
10-fold higher in the somatotrophinomas, and 3-fold higher in
the nonfunctioning adenomas. POU1F1 was overexpressed only
in the somatotrophinomas (3-fold increase). The results are
expressed as the means¡ SD of quadruplicate assays. *p,0.025.
ACTH_PA, ACTH-producing adenomas; GH_PA, GH-producing
adenomas; NF_A, nonfunctioning adenomas.
Figure 2 - Transcriptional profile of hormone-producing genes in
pituitary adenomas. POMC expression was 65-fold higher in the
corticotrophinomas. GH was constitutively expressed in almost
all of the somatotrophinoma samples analyzed. The expression
of hormone-producing genes was downregulated in the non-
functioning adenomas. The results are expressed as the means¡
SD of quadruplicate assays.
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expression of TBX19, while the nonfunctioning adenomas
presented a heterogeneous pattern of TBX19 expression.
Additionally, the TBX19 mRNA levels positively correlated
with POMC expression (r = 0.49, p = 0.014).
& DISCUSSION
Although pituitary adenomas do not usually metastasize,
these tumors result in high morbidity due to their
intracranial localization and/or excessive hormone produc-
tion. In this study, the transcriptional profile of genes
involved in early pituitary embryogenesis was analyzed in
pituitary adenomas, aiming to identify their role in
tumorigenesis and hormone hypersecretion.
TBX19 is present in normal pituitary glands, POMC-
expressing corticotropes that form in the anterior lobe, and
melanotropes that form in the intermediate lobe (10-12).
POU1F1 is essential for the development of the somato-
trope, lactotrope, and thyrotroph cell lineages in the anterior
pituitary and for the subsequent expression of GH, PRL,
and a-TSH (13-15). In this study, TBX19 and POU1F1 were
found to be overexpressed in corticotrophinomas and
somatotrophinomas, respectively, as has been previously
demonstrated (16-18).
The expression pattern of hormone-producing genes was
related to the functional category of the adenomas. ACTH
was overexpressed in the corticotrophinomas, and GH was
constitutively expressed in most of the somatotrophinomas
that were investigated in this study. The constitutive
expression of GH in somatotrophinomas has previously
been shown by microarray (4).
Interestingly, we found that the expression of PROP1 was
higher in the corticotrophinomas than in the somatotrophinomas.
This increased PROP1 expression in corticotrophinomas was
unexpected because Prop1 is not associated with corticotrope
differentiation, according to studies in murine models (15).
However, since our first report in 1999 (7), a progressive
decline in cortisol levels has been reported in a number of
patients with PROP1 loss-of-function mutations (19).
Although PROP1 gene expression in human pituitary
adenomas, including in corticotrophinomas (1), has been
confirmed, these results were only qualitatively demon-
strated using semiquantitative RT-PCR analysis. In contrast,
our work is the first to demonstrate the differential
expression of PROP1 in corticotrophinomas using quantita-
tive RT-PCR.
The increased expression of PROP1 in corticotrophinomas
that was observed in the present study supports a role for
PROP1 in the maintenance of cells committed to cortico-
trophic differentiation.
In conclusion, our data show that PROP1 is overexpressed
in pituitary adenomas, mainly in corticotrophinomas,
supporting a role for this transcription factor in pituitary
tumor development and also in the maintenance of cells
committed to corticotrophic differentiation.
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